IgA vasculitis
Drug research and approvals for igA vasculitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 21 studies of igA vasculitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 21
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 21 recruiting on ClinicalTrials.gov ↗
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic…NCT07822100 · Not applicable · Hong Zhang · starts Aug 24, 2026
- I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA VasculitisNCT07664228 · Not reported · Bursa City Hospital · starts May 15, 2026
- Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of…NCT07595367 · Phase 2 · Qifeng Zhang · starts Aug 10, 2026
- CD19/BCMA UCAR-T for B Cell-Related Autoimmune DiseaseNCT07586267 · Early Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts May 8, 2026
- Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseNCT07507201 · Early Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts Apr 1, 2026
- CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune DiseaseNCT07305116 · Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts Dec 1, 2025
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.NCT07203404 · Early Phase 1 · Nanjing Bioheng Biotech Co., Ltd. · starts Jul 24, 2025
- Study of Ravulizumab in Pediatric Participants With Primary IgANNCT07024563 · Phase 3 · Alexion Pharmaceuticals, Inc. · starts Jun 14, 2025
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications
Phase 3 1
- RituximabB-lymphocyte antigen CD20 binding agent
Phase 2 5
- PrednisoneGlucocorticoid receptor agonist
- LeflunomideDihydroorotate dehydrogenase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- CyclophosphamideDNA inhibitor
Phase 1 or earlier 2
- BenazeprilAngiotensin-converting enzyme inhibitor
- DipyridamoleEquilibrative nucleoside transporter 1 inhibitor
How its trials ended
35 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong- Completed, result not reported1131%
- Ongoing1131%
- Status unknown1131%
- Met its primary endpoint13%
- Missed its primary endpoint13%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA